表3.

225例肺腺癌患者肿瘤相关观察指标的单因素分析

Variables	Total (n=225)	VTE		P
		Negative (n=193)	Positive (n=32)
Site				0.32
Left	89 (39.56%)	73 (37.82%)	16 (50.00%)
Right	132 (58.67%)	117 (60.62%)	15 (46.88%)
Both	4 (1.77%)	3 (1.56%)	1 (3.12%)
Clinical stage				0.49
I-II	53 (23.56%)	47 (24.35%)	6 (18.75%)
III-IV	172 (76.44%)	146 (75.65%)	26 (81.25%)
Pulmonary metastasis				0.90
Without	181 (80.44%)	155 (80.31%)	26 (81.25%)
With	44 (19.56%)	38 (19.69%)	6 (18.75%)
Lymph node metastasis				0.36
Without	72 (32.00%)	64 (33.16%)	8 (25.00%)
With	153 (68.00%)	129 (66.84%)	24 (75.00%)
Distant metastasis				0.24
Without	99 (44.00%)	88 (45.60%)	11 (34.38%)
With	126 (56.00%)	105 (54.40%)	21 (65.62%)
Surgery				0.13
Without	142 (63.11%)	118 (61.14%)	24 (75.00%)
With	83 (36.89%)	75 (38.86%)	8 (25.00%)
Pulmonary infection				0.70
Without	214 (95.11%)	184 (95.34%)	30 (93.75%)
With	11 (4.89%)	9 (4.66%)	2 (6.25%)
Radiotherapy				<0.05
Without	206 (91.56%)	180 (93.26%)	26 (81.25%)
With	19 (8.44%)	13 (6.74%)	6 (18.75%)
Targeted therapy				<0.05
Without	94 (41.78%)	86 (44.56%)	8 (25.00%)
With	131 (58.22%)	107 (55.44%)	24 (75.00%)
Immunotherapy				0.75
Without	178 (79.11%)	152 (78.76%)	26 (81.25%)
With	47 (20.89%)	41 (21.24%)	6 (18.75%)
Pemetrexed				0.23
Without	22 (9.78%)	17 (8.81%)	5 (15.63%)
With	203 (90.22%)	176 (91.19%)	27 (84.37%)
Paclitaxel				0.79
Without	166 (73.78%)	143 (74.09%)	23 (71.88%)
With	59 (26.22%)	50 (25.91%)	9 (28.12%)
Platinum				0.86
Without	23 (10.22%)	20 (10.36%)	3 (9.38%)
With	202 (89.78%)	173 (89.64%)	29 (90.62%)
Period of chemotherapy (d)				0.37
Median (Q1, Q3)	126 (84, 189)	126 (84, 189)	126 (84, 168)
Period of immunotherapy (d)				0.50
Median (Q1, Q3)	126 (63, 237)	126 (63, 231)	136.5 (84, 283.5)